Kazia Therapeutics CEO Dr James Garner was a key speaker at a Finance News Network event in Sydney last week, where he was later by interviewed by FNN.
Watch the interview:
Watch Dr Garner’s presentation
Dr Garner presented:
- A brief update on the company’s clinical program for its potential recurrent ovarian cancer drug, Cantrixil
- An in-depth overview of the company’s lead program, GDC-0084, which is a potential drug for the brain cancer glioblastoma multiforme
- Brief overview of the company’s newest GDC-0084 collaboration, with St Judes Children’s Research Hospital
“Glioblastoma is a terrible disease… it still has one of the worst outcomes of any cancer,” Dr Garner said. “Sadly, it’s the disease that claimed the life of US Senator John McCain a few months ago, and it’s enormously difficult to treat because although there is a drug therapy available, that therapy only works for about one third of patients.
“We are developing GDC-0084 to target those two thirds of patients who will not benefit from the existing therapy.
“On available evidence, this looks to be a very safe and efficacious drug.”
